FDA Links 30+ IV Glutathione Reactions to Single Medisca Ingredient Lot Used by Compounding Pharmacies

Federal regulators have identified a common thread running through a string of injuries at wellness clinics: at least 30 patients experienced adverse reactions after receiving intravenous glutathione查看药品详情, and the compounding pharmacies involved all purchased the same ingredient from the same supplier lot.

The Food and Drug Administration (搜索)搜索该词条 named the source in an alert issued August 27. Different compounding pharmacies all obtained their glutathione查看药品详情 from Medisca Inc.查看公司主页, whose U.S. headquarters is in Plattsburgh, New York, under lot number 229536. That material was labeled as dietary supplement grade, which the agency states is not an appropriate ingredient for making injectable drugs.

The reported reactions were not mild. The agency lists fever, chills, pain, dizziness, signs of shock, and sepsis-like symptoms, noting that some patients are hospitalized. This represents a meaningful escalation from what was publicly known earlier this month, when two Texas pharmacies had each pulled product without any named upstream cause.

One Supplier Lot Links Two Separate Recalls

The agency says Medisca notified it on August 20 that the company had sent its United States customers a warning not to use its dietary-supplement-grade glutathione查看药品详情 to compound injectable drugs. Regulators are urging compounders who received that material to contact their own customers and tell them to discontinue use of the resulting product.

Two Texas pharmacies have already conducted recalls tied to elevated endotoxin (搜索)搜索该靶点 levels in glutathione查看药品详情 injections, as the agency's compounding alert confirms. MedicalDaily reported on the first, an Austin pharmacy that recalled three lots to the patient level after its own testing found elevated endotoxin, and on a Houston pharmacy recall whose product reached patients in 14 states.

At the time, the shared failure pointed to something upstream that had not been named. It now has been. That does not mean every compounded glutathione查看药品详情 product is affected, and the agency has not published a list of every pharmacy that received the lot.

This is also not the first time the agency has raised the issue. It flagged the same concern years earlier, in a 2019 communication about using dietary ingredient glutathione查看药品详情 to compound sterile injectables, and says it remains concerned about continued risks to patients.

Why Endotoxin Exposure Is Clinically Significant

Endotoxin (搜索)搜索该靶点 deserves a plain explanation because it behaves unlike an infection. It is a component of the outer membrane of certain bacteria and can remain in a product even after sterilization kills the organisms. A vial can pass a sterility test and still carry a hazardous endotoxin load. When injected directly into a vein, it can trigger a rapid and severe immune response.

The symptoms the agency describes are consistent with exposure to excessive endotoxin (搜索)搜索该靶点 levels: fever, chills, pain, dizziness, signs of shock and sepsis-like symptoms. The agency adds that endotoxin exposure can also cause muscle pain, headache, nausea, vomiting, low blood pressure, and death, while noting that not all of those outcomes have been reported in connection with these particular events.

Med Spa Customers Sit Outside the Recall Chain

The households most exposed here are the ones least likely to hear about a recall. Injectable glutathione查看药品详情 is marketed for skin brightening, cellular detoxification, immune support, and general wellness, and is typically administered at med spas, wellness clinics, and IV drip bars rather than in hospitals or doctors' offices, where safety notices are circulated through established channels.

A patient in that setting usually never sees a vial, a lot number, or a pharmacy name. Recall notices reach prescribers and clinics; they do not reach the person who booked an infusion online.

There is also a regulatory point worth stating plainly. The agency has not approved any injectable glutathione查看药品详情 product. Compounded drugs are not FDA-approved and do not undergo premarket review for safety, effectiveness, or quality. None of the uses being marketed rests on approved labeling.

Anyone considering an infusion can ask three questions before booking: which compounding pharmacy supplies the product, whether that pharmacy has had a recall this year, and what the lot number is. A clinic that cannot answer the first question cannot reach you if a recall arrives.

An Investigation That Is Still Open

Regulators say they continue to receive adverse event reports consistent with endotoxin (搜索)搜索该靶点 exposure and are actively investigating, with updates promised as more becomes available.

Several things remain unknown. The agency has not said how many compounding pharmacies received the affected material, how many patients were exposed, how many required hospitalization, or whether additional recalls will follow. It has not stated whether the 30 reported cases are confined to the two pharmacies that have already recalled product. No enforcement action against any company has been announced, and the identification of a supplier lot is not a finding of legal fault.

The agency's guidance to industry is direct: compounders are responsible for ensuring every component of an injectable drug is appropriate for its intended use, should know their ingredient suppliers, and should not rely on testing alone, because quality has to be built into every step of the process rather than caught at the end. Health care professionals are advised to check with their compounders about the source of the glutathione查看药品详情.

Consumers and clinicians can report problems through the MedWatch program, which is how the reports behind this alert accumulated. Anyone who feels unwell after a recent infusion should contact the clinician who administered it and mention the product and timing. Difficulty breathing, throat tightness, facial swelling, chest pain, fainting, confusion, or a rapidly spreading rash warrant emergency care rather than a phone call.